Glaukos (GKOS) The 44th Annual William Blair Growth Stock Conference summary

Strategic vision and product innovation

• Focus on transforming glaucoma care from topical drops to interventional solutions, highlighted by the development and launch of iDose, a micro-invasive drug delivery platform with up to three years of efficacy.

• Over $600 million invested in R&D, resulting in a robust pipeline including iStent, iDose, iLink, iLution, and retina programs.

• Expansion into new therapeutic areas such as keratoconus (iLink/Epioxa) and retina, with multiple next-generation products in clinical trials.

• Commitment to philanthropy by matching commercial iDose sales with donations to underserved populations.

Clinical and regulatory milestones

• iDose received FDA approval in December and launched in February, supported by pivotal trials showing up to 81% of patients medication-free at 12 months and nearly 70% maintaining efficacy at three years.

• Manufacturing facility built in-house after contract manufacturers declined, achieving FDA approval with zero 483B findings.

• Secured a permanent J code for iDose, effective July 1, streamlining reimbursement and facilitating broader market adoption.

Commercial strategy and market opportunity

• Controlled launch strategy for iDose, leveraging existing sales force and comprehensive reimbursement training for customer offices.

• Market opportunity for iDose estimated at over 1 million eyes, with a broad label enabling use across glaucoma severity.

• Revenue mix now diversified internationally and across product lines, with net sales guidance for 2024 between $357 million and $365 million.